WHO ICTRP trial
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of…
JPRN-jRCT2031210657 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031210657 |
|---|---|
| Public title | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) |
| Scientific title | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF RET FUSION-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER |
| Primary sponsor | Ahmadur Rahman |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Australia;Japan;Belgium;Japan;Denmark;Japan;Finland;Japan;France;Japan;Germany;Japan;Ireland;Japan;Italy;Japan;Republic of… |
| Conditions | RET-fusion Non Small Cell Lung Cancer |
| Interventions | Pralsetinib Hydrate: Pralsetinib Hydrate will be administered orally, once daily at a dose of 400 mg. Control Intervention: Platinum-based chemotherapy with or without pembrolizumab Participants randomized to the Active Comparator Arm will… |
| Registration date | Oct 3, 2022 |
| Target size | 226 |
| Secondary IDs | NCT04222972 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: